Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001

NCT05657184 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: REGEND001

Sponsor

Regend Therapeutics

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]